|
2/4/12 - FDA Approves Bydureon Once-Weekly Treatment for Type 2 Diabetes [Professional Services Close - Up]
|
|
Amylin Pharmaceuticals, Inc. and Alkermes plc announced that the U.S. Food and Drug Administration has approved Bydureon a once- weekly treatment for type 2 diabetes. "With Bydureon, U.S. physicians and patients can now choose a therapy that offers continuous blood sugar control in just one dose per week," said John Buse, M.D., Ph.D., professor of
|
|
2/4/12 - FDA Approves Cure for Snoring -- SnoreRx, a Painless and Inexpensive Mouth Guard, was Just Approved by the FDA to Cure Snoring According to Apnea Sciences Corporation
|
|
Laguna Hills, CA February 04, 2012. Apneas Sciences Corporation, after many years of research and development, has just secured FDA approval for its painless, non-surgical, and inexpensive cure for snoring. With over 75 million Americans who snore according to the Cleveland Clinic, this is a market changer.
|
|
2/4/12 - FDA Approves Inlyta To Treat Patients With Type of Advanced Kidney Cancer [Professional Services Close - Up]
|
|
The U.S. Food and Drug Administration approved Inlyta to treat patients with advanced kidney cancer who have not responded to another drug for this type of cancer. The group said Renal cell carcinoma is a type of kidney cancer that starts in the lining of very small tubes in the kidney. "This is the seventh drug that has been approved for the trea
|
|
2/3/12 - CANADA,UNITED STATES : FDA Approves JANUMET XR (sitagliptin and metformin HCl extended-release) for Type 2 Diabetes, Offering the Powerful Efficacy... [TendersInfo (India)]
|
|
Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration approved JANUMET XR (sitagliptin and metformin hydrochloride extended-release) tablets, a new treatment for type 2 diabetes that combines sitagliptin, which is the active component of JANUVIA, with extended-release metformin.
|
|
2/3/12 - Depomed Announces FDA Approval of Merck's JANUMET XR That Accesses Depomed Patents Licensed to Merck
|
|
Depomed, Inc. today announced that Merck disclosed on February 2, 2012 that the U.S. Food and Drug Administration approved JANUMET ® XR tablets, a new treatment for type 2 diabetes that combines sitagliptin, which is the active component of JANUVIA ®, with extended-release metformin. Depomed has provided Merck a license to certain of Depomed's pa
|
|
2/3/12 - Depomed Announces FDA Approval of Merck's JANUMET(R) XR That Accesses Depomed Patents Licensed to Merck
|
|
MENLO PARK, Calif., Feb. 3, 2012-- Depomed, Inc. today announced that Merck disclosed on February 2, 2012 that the U.S. Food and Drug Administration approved JANUMET ® XR (sitagliptin and metformin hydrochloride extended-release) tablets, a new treatment for type 2 diabetes that combines sitagliptin, which is the active component of JANUVIA ®, wi
|
Chain Drug Review, established in 1978 and published 21 times a year, is recognized as the premier news publication serving the entire chain drug store industry.
Featured Article from Chain Drug Review:
AWP suit settlement appealed
The National Association of Chain Drug Stores has appealed a U.S. District Court’s approval of settlements in the First DataBank Inc. and Medi-Span Inc. lawsuit.
»read more
|
|
|
